69
Acute Respiratory Disorder NP02L029

M6_PP02L029_Acute Respiratory Disorders (v 1.4)

  • Upload
    blaks85

  • View
    226

  • Download
    0

Embed Size (px)

Citation preview

Page 1: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 1/69

Acute Respiratory Disorder

NP02L029

Page 2: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 2/69

Terminal Learning Objective

Given a patient with an acute respiratory

disorder, determine approaches for patient

care by correctly responding to written,oral and experiential assessment measures.

Page 3: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 3/69

Enabling Learning Objectives

A: Examine the etiology/pathophysiology, clinicalmanifestations, assessment diagnosis, medical

management and nursing interventions of a

 patient with a pneumothorax.

B: Describe the pathophysiology, clinical

manifestations, assessment diagnosis, medical

management and nursing interventions of lungcancer.

Page 4: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 4/69

Enabling Learning Objectives

  C: Describe the pathophysiology, clinical

manifestations, assessment diagnosis, medical

management and nursing interventions of 

 pulmonary edema.

D. Examine the etiology/pathophysiology,

clinical manifestations, assessmentdiagnosis,

medical management and nursing

interventions of 

Page 5: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 5/69

Enabling Learning Objectives

E: Describe the etiology/pathophysiology,

clinical manifestations, assessment diagnosis,

medical management and nursing interventions of 

a patient with Acute Respiratory DistressSyndrome.

F. Explain the pharmacological and nursingimplications of mucolytic agents

Page 6: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 6/69

Pneumothorax

Etiology/Pathophysiology Air or gas in the pleural space, causing the lung

to collapse

Causes

Chest trauma

Ruptured bleb

Pleural lining injury

Spontaneous

Interrupts the normal negative pressure, keeping thelung from remaining inflated

Page 7: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 7/69

Page 8: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 8/69

Page 9: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 9/69

Pneumothorax

Tension pneumothorax

Build up of air in the pleural space, causing

interference with the ability of the heart and lungs

to fill 

Life threatening

Page 10: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 10/69

Pneumothorax

Clinical Manifestations- patient may present with arecent chest injury

Decreased breath sounds on affected side

Sharp pleuritic pain, dyspnea

Diaphoresis, tachycardia

Tachypnea

Abnormal chest movement

Possible sucking chest wound on inspiration Hypoxia

Shifting of mediastinum

Hypotension

Page 11: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 11/69

Pneumothorax

Assessment

Inquire to a recent injury or coughing

episode

May c/o shortness of breath, anxiety,

hypoxia

Breath sounds unequal, or diminished

 

Page 12: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 12/69

Pneumothorax

Assessment (cont)

Penetrating or blunt wounds to the chest,unequal movement with flail segements

Assess respiratory and cardiac, rate andrhythm

Monitor vital signs frequently

 Note color characteristics, and amount of sputum

Page 13: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 13/69

Pneumothorax

Diagnostic tests

Chest x-ray

ABG

Medical management

 Needle thoracostomy

Chest Tube

Heimlich valve/water-seal suction

Page 14: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 14/69

Pneumothorax

 Nursing interventions- maintain airway

 patency and oxygenation

Assess and document patency of chest tube

Provide analgesics

Assist with coughing and deep breathing

Splint or support Observe

Page 15: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 15/69

Pneumothorax

 Nursing interventions(cont)

Patient teaching

Increase fluid intake

Avoid fatigue

Report signs and symptoms of recurrence

Page 16: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 16/69

Pneumothorax

 Nursing diagnosis 

Breathing pattern ineffective r/tnonfunctioning lung

Fear related to feeling of air hunger 

Page 17: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 17/69

Check on Learning

List three signs of a pneumothorax:

a.----------------------

 b.----------------------

c.----------------------

Page 18: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 18/69

Check on Learning :

List three signs of a pneumothorax:

Decreased breath sounds on

the affected side

 Sharp, pleuritic pain withdyspnea

Diaphoresis, tachycardia

Tachypnea

Hypoxia

Abnormal chest movement

If penetrating injury may

hear sucking sounds on

inspiration

Shifting of the mediastinum

to the unaffected side with

compression of the great

vessels

Hypotension - due to

decrease in venous return to

the heart and poor cardiac

filling

Page 19: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 19/69

Lung Cancer 

Etiology/Pathophysiology Leading cause of cancer related death in men and

women Accounts for 28% of all cancer deaths

Tumors, 80-90% r/t cigarettes

Second hand smoke, asbestos and air pollution

Mortality

Treatment

Page 20: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 20/69

Page 21: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 21/69

Lung Cancer 

Types of lung cancer 

Small cell

 Non-small cell

Squamous cell carcinoma

Large cell

Page 22: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 22/69

Page 23: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 23/69

Lung Cancer 

Assessment

Chronic hoarseness

Chronic cough

History of smoking or environmental

exposure

Weight loss

Page 24: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 24/69

Lung Cancer 

Assessment(cont) Hemoptysis

Shortness of breath, wheeze Pleural effusion

Edema of face or neck 

Friction rub Clubbing of fingers

Pericardial effusion

Page 25: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 25/69

Lung Cancer 

Diagnostic tests Chest X-Ray

CT

MRI Bronchoscopy

 Needle aspiration

Biopsy Mediastinoscopy

Scalene lymph node biopsy

Page 26: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 26/69

Lung Cancer 

Medical management- depends on type and

stage of lung cancer 

Estimated 1/3 of patients inoperable when first

diagnosed

Another 1/3 found inop during exploratory

thoracotomy Surgical treatment-1/3 experience tumor 

spread

Page 27: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 27/69

Lung Cancer 

Surgical treatment Pneumonectomy

Lobectomy

Segmental resection

Video assisted thorascopic surgery

Radiation and chemotherapy

SCLC chemotherapy

Page 28: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 28/69

Lung Cancer 

 Nursing interventions- directed at improvingquality of life

General nursing measures Monitor antineoplastic side effects

Reduce exertion

Maintain body weight

Relieve pain, administer analgesics

Encourage patient to stop smoking

American Cancer Society resourses

Page 29: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 29/69

Lung Cancer 

 Nursing diagnosis and interventions Airway clearence ineffective r/t lung

surgery Facilitate optimal breathing

Encourage ambulation

Position changes Cough deep breathe

Assess breath sounds

Page 30: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 30/69

Lung Cancer 

 Nursing diagnosis and interventions(cont) Fear r/t cancer treatment and prognosis

Explain treatments and procedures

Listen to the patient, accept feelings of anger 

Encourage verbalization of feelings Supportive services

Monitor for signs and symptoms of worthlessness,anxiety, powerlessness

  Prognosis-10-15% live 5 years or longer Survival rate- 40% for cancers identified in localstage

Page 31: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 31/69

Pulmonary Edema

Etiology/Pathophysiology Accumulation of serous fluid in interstitial lung

tissue and alveoli Results from Severe left ventricular failure

Inhalation of irritating gases

Rapid administration of I.V. fluids

Barbiturate and opiate overdose

Page 32: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 32/69

Page 33: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 33/69

Pulmonary Edema

Serous fluid forced into alveoli

Gas diffusion severely affected

Acute

Can lead to death if untreated

Page 34: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 34/69

Pulmonary Edema

Clinical manifestations Dyspnea

Tachypnea Tachycardia

Hypoxia, cyanosis

Pink frothy sputum

Restlessness, agitation

Page 35: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 35/69

Pulmonary Edema

Assessment  Note c/o dyspnea

May express feeling of impending death Assess for signs and symptoms of resp distress

Wheezing and crackles

Weight gain Decreased urinary output

Productive cough with frothy pink sputum

Page 36: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 36/69

Pulmonary Edema

Diagnostic tests

CXR 

ABG

Medications

Oxygen therapy

Lasix

Morfine sulfate

 Nipride

Digoxin

Page 37: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 37/69

Pulmonary Edema

 Nursing interventions

Assess respiratory status frequently

O2 therapy

Volume status

Patient teaching

Prognosis

Page 38: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 38/69

Pulmonary Embolus

Clinical manifestations Chest pain

Dyspnea

Tachypnea

Hemoptosis

Diminished lung sounds

Elevated temperature

Hypotension

Regional bronchoconstriction, Atelectasis

Pulmonary edema, decreased surfactant

Page 39: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 39/69

Page 40: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 40/69

Page 41: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 41/69

Page 42: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 42/69

Pulmonary Embolus

Diagnostic tests ABG’s

CXR  CT angiogram

V/Q scan

Pulmonary arteriogram

D-dimer 

Venous ultrasound

Page 43: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 43/69

Page 44: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 44/69

Pulmonary Embolus

Nursing interventions Assess sensorium

Monitor cardiorespiratory status DVT treatment

Assess for signs of bleeding

Patient teaching

Prognosis- 30% mortality rate if untreated.

5% mortality with early diagnosis and treatment

Page 45: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 45/69

ARDS

Etiology/Pathophysiology Also called non-cardiogenic pulmonary edema

Secondary to an acute disease process, asyndrome of pulmonary shunting , hypoxemia,reduced lung compliance and parenchymal lungdamage 

Page 46: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 46/69

Page 47: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 47/69

Page 48: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 48/69

ARDS

Pathophysiology

Surface of alveolar capillary membrane becomes

altered Fluid leaks into the interstitial space and alveoli

Results in pulmonary edema and hypoxia

Alveoli lose elasticity and collapse Pulmonary artery hypertension

Page 49: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 49/69

ARDS

Clinical manifestations

Usually manifests in 12-24 hours post surgery

Respiratory distress with altered breath sounds

within 5-10 days

Altered sensorium

Tachycardia

Page 50: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 50/69

ARDS

Assessment

Obtain background information

Observe changes in patients condition Assess respiratory rate rhythm and effort

Assess for nasal flaring, retractions, or cyanosis

Assess for crackles and wheezing

Assess level of consciousness

Page 51: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 51/69

ARDS

Diagnostic tests

Pulmonary functions tests

ABG’s CXR 

Page 52: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 52/69

ARDS

Medical management – focuses on supportave

treatment by maintaining adequate

oxygenation and treating the cause

Page 53: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 53/69

ARDS

Medications

Diuretics

Morphine sulfate

Digoxin

Antibiotics

Ventilatory support

 Nitric oxide

Page 54: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 54/69

ARDS

 Nursing interventions and patient teaching

  Goal: Provide adequate oxygenation and

ventilation and treat multi system response to

ARDS Monitor respiratory status

Assess vital signs

Position patient to facilitate optimal ventilation Turn cough deep breath

Page 55: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 55/69

ARDS

 Nursing diagnosis

Gas exchange impaired r/t tachypnea

 Nursing interventions

Monitor ABG’s

Monitor for restlessness

Administer oxygen

Report v/s changes and L.O.C.

Page 56: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 56/69

ARDS

 Nursing diagnosis Breathing pattern, ineffective r/t respiratory

distress Nursing interventions

Assess respiratory rate rhythm and effort

Proper positioning Maintain airway patency and promote

C/DB

Page 57: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 57/69

Mucolytics  A mucolytic is a drug that loosens

respiratory secreations.

Use: Bronchitis.

Cystic Fibrosis.

COPD. Atelectasis.

Acetaminophen toxicity.

Page 58: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 58/69

Mucolytics Con’t

Actions:

Decreases viscosity of secretions by breakingdisulfide links of mucoproteins.

Serves as a substrate in place of glutathione,which is necessary to inactivate toxicmetabolites in acetaminophen overdose.

Example: acetylcysteine (Acetadote, Mucomyst).

Page 59: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 59/69

Mucolytics Con’t

Contraindications:

Hypersensitivity.

Increased intracranial pressure.

Status asthmaticus.

Precautions:

Pregnancy.

Hypothyroidism.

Addison’s Disease.

Page 60: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 60/69

Mucolytics Precautions Con’t

CNS depression. Brain tumor.

Asthma.

Renal / heptic disease.

COPD.

Psychosis.

Alcoholism. Convulsive disorders.

Breastfeeding.

Page 61: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 61/69

Mucolytics Side Effects

CNS: dizziness, drowsiness.

CV: hypotension.

EENT: rhinorrhea. GI: nausea, stomatitis, constipation, vomiting,

anorexia, hepatotoxicity.

Integ: urticaria, rash, fever, clamminess, pruritus.

Resp: bronchospasm, hemoptysis, chesttightness.

Page 62: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 62/69

Mucolytics Con’t

Interactions:

Do not use with iron, copper, rubber.

Do not mix with antibiotics. Increases the effects of nitrates.

Page 63: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 63/69

Mucolytics Nursing Implications

Assessment: Cough: type, frequency, character, including

sputum.

VS: resp rate, rhythm, increased dyspnea.

CV: dysrthythmias.

Lab Tests: ABGs (increased CO2: asthma).

Page 64: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 64/69

Mucolytics Nursing Implementation

Administration (PO):

Mix with soft drinks to disguise taste. (Give

within one hour). Give ½ - 1 hour before meals for better 

absorption and to decrease nausea.

Assistance with inhaled dose: bronchodilator if 

 bronchospasm occurs.

Page 65: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 65/69

Mucolytics Nursing Implementation Con’t

Antidotal: within 24 hours.

Store in refrigerator (up to 96 hours after 

opening).

Gum, hard candy, frequent rinsing of mouth for 

dryness of oral cavity.

Page 66: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 66/69

Mucolytics Patient Teaching

About mucolytic use.

Unpleasant odor will decrease after repeated use.

Discoloration of solution after opening, does notaffect effectiveness of medication.

Report vomiting, since dose may need to berepeated.

Page 67: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 67/69

Mucolytics Evaluation

Absence of purulent secretions.

Absence of hepatic damage in

acetaminophen toxicity.

View:videos.howstuffworks.com/discover 

y-health/14598-human-atlas-mucolytics-video.htm

Page 68: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 68/69

Check on Learning

Question: What is the action of 

Mucolytics?

Answer:

Loosens respiratory secretions.

Reduces the viscosity of respiratory secretions by direct action on the mucus.

Page 69: M6_PP02L029_Acute Respiratory Disorders (v 1.4)

8/4/2019 M6_PP02L029_Acute Respiratory Disorders (v 1.4)

http://slidepdf.com/reader/full/m6pp02l029acute-respiratory-disorders-v-14 69/69

REVIEW

Pneumothorax

Lung cancer 

Pulmonary edema

Pulmonary embolus

ARDS

Mucolytics